Clinical Trial Update: Comparison of PKs of 17-Beta-Estradiol Via Sublingual Placement Versus Swallowing in Male-to-Female Transgender Patients [Phase 4]

View source ↗

Summary

Phase 4 trial comparing pharmacokinetics of 17-Beta-Estradiol given sublingually versus swallowed in male-to-female transgender patients has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gender Dysphoria

Drugs mentioned

• 17-Beta Estradiol (17-beta estradiol)

Snippet

Sponsor: MaineHealth | Conditions: Gender Dysphoria | Phase 4 | Status: TERMINATED